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Abstract 
Background: Activated platelets release platelet extracellular vesicles (PEVs). Adenosine diphosphate 
(ADP) receptors P2Y1 and P2Y12 both play a role in platelet activation, The present hypothesis herein 
is that the inhibition of these receptors may affect the release of PEVs.
Methods: Platelet-rich plasma from 10 healthy subjects was incubated with saline, P2Y1 antagonist 
MRS2179 (100 µM), P2Y12 antagonist ticagrelor (1 µM), and a combination of both antagonists. 
Platelets were activated by ADP (10 µM) under stirring conditions at 37°C. Platelet reactivity was 
assessed by impedance aggregometry. Concentrations of PEVs– (positive for CD61 but negative for  
P-selectin and phosphatidylserine) and PEVs+ (positive for all) were determined by a state-of-the-art 
flow cytometer. Procoagulant activity of PEVs was measured by a fibrin generation test.
Results: ADP-induced aggregation (57 ± 13 area under curve {AUC] units) was inhibited 73%  
by the P2Y1 antagonist, 86% by the P2Y12 antagonist, and 95% when combined (p < 0.001 for all). 
The release of PEVs– (2.9 E ± 0.8 × 108/mL) was inhibited 48% in the presence of both antagonists  
(p = 0.015), whereas antagonists alone were ineffective. The release of PEVs+ (2.4 ± 1.6 × 107/mL) 
was unaffected by the P2Y1 antagonist, but was 62% inhibited by the P2Y12 antagonist (p = 0.035), 
and 72% by both antagonists (p = 0.022). PEVs promoted coagulation in presence of tissue factor. 
Conclusions: Inhibition of P2Y1 and P2Y12 receptors reduces platelet aggregation and affects the 
release of distinct subpopulations of PEVs. Ticagrelor decreases the release of procoagulant PEVs from 
activated platelets, which may contribute to the observed clinical benefits in patients treated with tica-
grelor. (Cardiol J 2019; 26, 6: 782–789) 
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Introduction
Platelet activation and aggregation in response 
to atherosclerotic plaque rupture is a key event in 
the pathogenesis of acute coronary syndrome (ACS) 
[1]. Platelet P2Y1 and P2Y12 receptors for adenosine 
diphosphate (ADP) contribute to ACS by initiating 
and amplifying platelet activation, respectively [2]. 
Whereas antagonists against the P2Y1 receptor are 
under development [3], antagonists against the P2Y12 
receptor are clinically established to prevent recurrent 
cardiovascular events in patients with ACS [4].
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In the course of ACS, activated platelets re-
lease fragments of their outer cell membrane to 
the bloodstream, called platelet-derived extracel-
lular vesicles (PEVs) [5]. A transmission electron 
microscope image of PEVs from human plasma is 
shown in Figure 1. PEVs are nanoparticles sur-
rounded by a phospholipid membrane which en-
closes cytoplasmic components such as proteins, 
lipids, metabolites and nucleic acids, they also 
contain platelet-derived proteins [5]. The expo-
sure of glycoprotein (GP) IIb/IIIa, a receptor for 
fibrinogen (CD41/CD61) enables identification of 
PEVs released from platelets or megakaryocytes 
among other extracellular vesicles (EVs) present 
in blood. In turn, the exposure of GP IIb/IIIa along 
with P-selectin (CD62P) and phosphatidylserine (PS), 
which enables identification of PEVs released from 
activated platelets [6]. PEVs exposing P-selectin and 
PS are likely involved in inflammation and thrombo-
sis [7–10]. P-selectin initiates binding of platelets 
and PEVs to monocytes via P-selectin glycoprotein 
ligand-1 (PSGL-1), leading to monocyte activation, 
cytokine release and exposure of tissue factor (TF) 
on monocytes [9]. PS along with other negatively 
charged phospholipids bind clotting factors in the 
presence of calcium ions, thereby propagating throm-
bin generation [10]. Hence, PEVs exposing P-selectin 
and PS may potentially contribute to the development 
and progression of atherosclerosis [11–13].
Although the potential applications of PEVs 
as biomarkers [14], risk predictors [15] and thera-
peutic targets [16] in cardiovascular disease are 
recognised, the mechanisms underlying the release 
of PEVs are unclear [17]. Because both P2Y1 and 
P2Y12 receptors regulate platelet activation, it was 
hypothesized that inhibition of these receptors may 
affect the release of PEVs. 
Methods
The design of the experiments is shown in 
Figure 2.
Figure 2. The design of the experiments on the role of the P2Y1 and P2Y12 receptors in the release of platelet 
extracellular vesicles. CaCl2 — calcium chloride; ADP — adenosine diphosphate; CD — cluster of differentiation; 
PEVs — platelet extracellular vesicles.
Incubation of platelet-rich plasma (PRP) with P2Y1 and P2Y12 antagonist (30 min)
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     • CD61 (glycoprotein IIIa)
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Figure 1. A transmission electron microscope image of 
platelet extracellular vesicles from human plasma. The 
vesicles were labelled with gold nanoparticles conjugat-
ed to CD61 antibodies. Image courtesy of Chi M. Hau, 
Vesicle Observation Center, Academic Medical Center, 
University of Amsterdam, the Netherlands.
Materials
Trisodium citrate blood collection tubes were 
obtained from Sarstedt (Germany). Needles were 
obtained from Vygon (Belgium). The P2Y1 an-
tagonist MRS2179 was obtained from Tocris Bio-
sciences (United Kingdom [UK]). The P2Y12 
antagonist ticagrelor was obtained from Cayman 
Chemical (USA), ADP was from Bio/Data Cor-
poration (USA), and acid citrate dextrose (ACD), 
phosphate-buffered saline (PBS), sodium citrate 
and calcium chloride (CaCl2) were obtained from 
Sigma Aldrich (USA). The Multiplate analyser and 
reagents were from Roche Diagnostics (Germany), 
lactadherin-FITC from Hematologic Technologies 
(USA), CD61-APC from Dako (Denmark), and 
CD62P-violet and isotype controls from Becton 
Dickinson (USA). The membrane (0.05 nm) to 
filtrate the buffers was obtained from Merck Mil-
lipore (Germany). The Rosetta Calibration beads 
were obtained from Exometry (The Netherlands). 
Innovin (recombinant human TF) was obtained 
from Siemens (Germany) and anti-factor VIIa from 
Sanquin (The Netherlands). 
Blood collection and handling 
Blood samples were obtained from 10 healthy, 
drug-free donors after overnight fasting and giving 
informed consent, according to the recent guide-
lines [18]. Blood was collected using a 19 gauge 
needle and a plastic tube containing citrate (final 
concentration 0.109 mol/L). The tourniquet was re-
moved promptly after the venepuncture. The first 
2.5 mL of blood collected was discarded to avoid 
pre-activation of platelets. The tubes were kept in 
a vertical position for 15 min. Platelet rich plasma 
(PRP) was prepared by centrifugation of blood for 
180 g at 15 min. Centrifugation was performed 
using Rotina 380 R centrifuge equipped with 
a swing-out rotor and a radius of 155 mm (Hettich 
Zentrifugen, Germany) at room temperature with 
acceleration speed 1, without brake. 
Aggregometry
288 µL of citrated PRP was added to 288 µL 
saline and incubated for 30 min at 37°C with 
(i) saline, (ii) P2Y1 receptor antagonist MRS2179 
(final concentration 100 µM), (iii) P2Y12 receptor 
antagonist ticagrelor (final concentration 1 µM), 
and (iv) a combination of both antagonists. Sub-
sequently, the diluted PRP was re-calcified (final 
concentration 2.5 mM CaCl2) before addition of 
ADP (10 µM). Platelet aggregation was recorded 
for 6 min while stirring using Multiplate analyser 
(Roche Diagnostics, Germany). 
Flow cytometry
Platelet-free supernatant was prepared by cen-
trifugation of 600 µL PRP with 120 µL ACD at 800 g 
for 20 min. PEVs were measured in this platelet-
free supernatant collected 30 min after the addi-
tion of ADP. Prior to labelling of the supernatant, 
antibodies were diluted in PBS and centrifuged at 
18,890 g for 5 min to remove protein aggregates. To 
stain, 20 µL of the supernatant was incubated with 
2.5 µL CD61-APC, 2.5 µL CD62P-violet, 2.5 µL 
lactadherin-FITC or isotype controls in the dark for 
2 h at room temperature. The reaction was stopped 
by adding 200 µL citrated PBS solution, adjusted 
to pH 7.4 and filtered with a 0.05 µm membrane 
prior to use [18]. PEVs released from platelets 
(positive for CD61 but negative for P-selectin 
and PS) are further referred to as PEVs–. PEVs 
released from activated platelets (positive for all) 
are referred to as PEVs+ [6]. PEV concentrations 
were determined by A60 Micro flow cytometer 
(Apogee Flow Systems, UK) for 60 s at a flow rate 
of 3.01 µL/min. Prior to measurement, the samples 
were diluted with PBS to 5,000 events per second 
to avoid swarm [19]. The applied voltages were 
375 V, 520 V, 510 V, and 500 V for the side scatter 
detector, FITC detector, APC detector, and violet 
detector, respectively. The gains were 1. The trig-
ger threshold was set on side scatter channel 10. 
Rosetta Calibration was used to relate side scatter 
to the diameter of PEVs, assuming a PEV refractive 
index of 1.4 [20].
The fluorescent gates were based on the 
isotype controls. To analyse the concentrations of 
PEVs–, in the first step all PEVs exposing CD62P 
and PS were gated out, and PEVs exposing CD61 
only were detected in the red channel (638-D Red). 
To analyse the concentrations of PEVs+, in the 
first step all plasma EVs exposing PS (binding to 
lactadherin) were detected in the green channel 
(488-Green). Out of all PEVs exposing PS, PEVs 
exposing additionally CD61 and CD62P were 
detected in the red channel (638-D Red) and blue 
channel (405-Blue). At the time of the experiment, 
no suitable beads to calibrate molecules of equiva-
lent soluble fluorophores (MESF) were available 
for the APC and violet channel. Therefore, gates 
were set in arbitrary units (AU) with the follow-
ing values: 4,153 AU for CD61-APC; 6,185 AU for 
CD62P-violet and 2,661 AU for lactadherin-FITC. 
Fibrin generation test 
The ability of PEVs to generate fibrin was 
measured in platelet-free plasma in the absence or 
presence of human recombinant TF (coagulation 
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factor VII), antibody against factor VIIa (anti-factor 
VIIa) and excess of lactadherin [21]. After pre-
incubation for 5 min at 37°C, clotting was initiated 
by addition of CaCl2. Fibrin formation over 1 h 
was determined by measuring the optical density 
(l = 405 nm) in duplicate on a spectrophotometer 
(SPECTRAmax microplate reader, Molecular De-
vices, USA) at 37°C. 
Statistical analysis
Kolmogorov-Smirnov test was used to test 
for Gaussian distribution. Data were analysed 
by paired Student’s t-test. A Spearman rank cor-
relation test was used to assess the correlation 
between aggregation results and concentration 
of PEVs. Statistical analysis was performed with 
the STATISTICA 12.0 (StatSoft, USA) and Prism 
7.0 (GraphPad, USA) software. Flow cytometry 
data was analysed with FlowJo 9.2 (FlowJo, USA). 
Data are presented as mean ± standard deviation. 
All p-values are given as two-sided values, with 
a p-value < 0.05 considered significant. 
Results
Size distribution of PEVs
Activation of platelets with ADP triggered 
platelet aggregation and the release of PEVs, 
compared to unstimulated platelets. The release 
of PEVs– and PEVs+ in response to ADP is shown 
in Figure 3. Scatter-based size distribution of the 
total population of PEVs (CD61+) confirmed that 
PEVs ranged from 150 nm to 1,000 nm in diameter, 
with the majority of PEVs being below 200 nm. 
Size distribution of the total population of PEVs is 
shown in Supplementary Figure 1. Please note, 
that plasma contains (platelet) EVs down to 30 nm, 
which are below the lower detection limit of flow 
cytometry [22].
The effects of ADP receptor antagonists on 
platelet aggregation and release of PEVs 
Adenosine diphosphate-induced aggregation 
(57 ± 13 area under curve [AUC] units) was 73% 
inhibited by the P2Y1 antagonist alone, 86% by 
Isotype control
A
B
CD61–APC (+)
0.068
CD61–APC (+)
3.29
CD61–APC (+)
8.45
CD61–APC (a.u.)
CD61–APC (a.u.)
CD61–APC (a.u.)
CD61–APC (a.u.)
CD61–APC (a.u.)
CD61–APC (a.u.)
2
10
2
10
2
10
2
10
2
10
2
10
2
10
2
10
2
10
2
10
2
10
2
10
3
10
3
10
3
10
3
10
3
10
3
10
3
10
3
10
3
10
3
10
3
10
3
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
4
10
5
10
5
10
5
10
5
10
5
10
5
10
5
10
5
10
5
10
5
10
5
10
5
10
6
10
6
10
6
10
6
10
6
10
6
10
6
10
6
10
6
10
6
10
6
10
6
10
7
10
7
10
7
10
7
10
7
10
7
10
7
10
7
10
7
10
7
10 Q1
0.63
Q1
0.22
Q1
0.64
Q4
90.2
Q4
99.7
Q4
95.7
Q2
0.67
Q2
0.16
Q2
0.38
Q3
8.47
Q3
0.10
Q3
3.28
7
10
7
10
F
o
rw
a
rd
 s
c
a
tt
e
r 
(a
.u
.)
C
D
6
2
P
-v
io
le
t 
(a
.u
.)
C
D
6
2
P
-v
io
le
t 
(a
.u
.)
C
D
6
2
P
-v
io
le
t 
(a
.u
.)
F
o
rw
a
rd
 s
c
a
tt
e
r 
(a
.u
.)
F
o
rw
a
rd
 s
c
a
tt
e
r 
(a
.u
.)
Unstimulated plasma Stimulation with ADP
Figure 3. Representative images of platelet extracellular vesicles (PEVs) from adenosine diphosphate-activated plate-
lets in plasma of a healthy donor measured by flow cytometry (A60-Micro, Apogee Flow Systems, Hertfordshire, 
UK); A. PEVs exposing CD61 but not CD62P and phosphatidylserine (PS) and labelled with anti-CD61-APC; B. PEVs 
exposing CD61, CD62P and PS and labelled with anti-CD61-APC, anti-CD62P-Violet and lactadherin-FITC, respectively. 
In the first step all plasma extracellular vesicles exposing PS (binding to lactadherin) were recorded (data not shown). 
Out of all PEVs exposing PS, PEVs exposing CD61 and CD62P were recorded (Q2); a.u. — arbitraty units.
www.cardiologyjournal.org 785
Aleksandra Gasecka et al., Ticagrelor inhibits the release of platelet extracellular vesicles
the P2Y12 antagonist alone, and 95% when both 
antagonists were combined (p < 0.001 for all; 
Fig. 4A). The release of PEVs– (2.9 ± 0.8 × 108 
events/mL) was unaffected by pre-incubation with 
the P2Y1 antagonist or by the P2Y12 antagonist 
alone, but decreased by 50% in presence of both 
antagonists (p = 0.015; Fig. 4B). In contrast, the 
release of PEVs+ (2.4 ± 1.6 × 107 events/mL) 
was unaffected by the P2Y1 antagonist alone, but 
was decreased 62% by the P2Y12 antagonist alone 
(p = 0.035), and 72% in the presence of both an-
tagonists (p = 0.022; Fig. 4C). Whereas the extent 
of platelet aggregation weakly correlated with the 
concentration of PEVs– (r2 = 0.2), the extent of 
platelet aggregation strongly correlated with the 
release of PEVs+ (r2 = 0.7, Fig. 4D). 
Procoagulant activity of PEVs
Platelet-free plasma containing PS-exposing 
EVs from ADP-activated platelets did not clot up to 
1 h after re-calcification. When human recombinant 
TF was added, clotting was initiated. The magni-
tude of clotting was not affected by the presence or 
absence of P2Y1 and P2Y12 antagonists (data not 
shown). Clotting was abolished both by covering 
the PS by an excess of lactadherin and by inhibit-
ing TF activity with anti-factor VIIa. The proposed 
procoagulant activity of PEVs measured with fibrin 
generation test is shown in Figure 5.
Discussion
P2Y1 and P2Y12 receptors differentially regu-
late platelet aggregation and the release of PEVs. 
Inhibition of either P2Y1 or P2Y12 receptor is suf-
ficient to inhibit ADP-induced platelet aggregation 
[23], which is consistent with the clinical observa-
tion that P2Y12 antagonists reduce the incidence 
of thrombosis in patients after ACS [4]. Further, 
inhibition of the P2Y1 and P2Y12 receptors affects 
Figure 4. The effect of platelet pre-incubation with a P2Y1 antagonist, a P2Y12 antagonist  and a combination of both 
antagonists on platelet aggregation (A) and the release of platelet extracellular vesicles (PEVs) exposing CD61 but 
not CD62p and phosphatidylserine (PS) (B) and PEVs exposing CD61, CD62p and PS (C) in response to adenosine di-
phosphate (ADP). Whereas platelet aggregation correlated weakly with the concentration of CD61+/CD62P–/PS– PEVs, 
platelet aggregation correlated strongly with the concentration of CD61+/CD62P+/PS+ PEVs (D).
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the release of distinct subpopulations of PEVs 
upon activation by ADP. The P2Y12 antagonist 
ticagrelor alone does not inhibit the release of 
PEVs–, suggesting that PEVs– may circulate in 
patients treated with ticagrelor and contribute to 
platelet homeostasis, for example by waste man-
agement [24]. On the contrary, ticagrelor decreases 
the release of PEVs+, that is PEVs exposing the 
proinflammatory P-selectin and procoagulant PS, 
suggesting that this subpopulation of PEVs may 
be decreased in patients treated with ticagrelor. 
In accordance, other P2Y12 receptor antagonists 
(clopidogrel, prasugrel and cangrelor) were shown 
to decrease the release of EVs from activated plate-
lets as well [25–27], although the phenotype of the 
analysed PEVs was different than in the present 
study. Clopidogrel decreased the release of PEVs 
(CD42a+, PS+) in response to thrombin receptor-
activating peptide (TRAP) in a group of 12 patients 
with ACS [25]. Similarly, both prasugrel active me-
tabolite and cangrelor decreases the collagen- and 
TRAP-induced release of PEV (CD42a+, PS+) in a 
concentration-dependent manner in experimental 
conditions [26, 27]. 
Inhibition of P-selectin- and PS-exposing 
PEVs may. at least partly, explain the combined 
anti-thrombotic and anti-inflammatory benefits 
of the P2Y12 receptor antagonists. The potential 
proinflammatory and procoagulant effects of PEVs 
are presented in Figure 6. Although PS-exposing 
EVs, such as those present in the plasma of healthy 
individuals, do not initiate coagulation in the ab-
sence of TF, PS-exposing EVs promote coagulation 
by providing a procoagulant surface. This proco-
agulant surface may be crucial in the ACS setting, 
where TF is exposed on a ruptured atherosclerotic 
plaque [28], and where PS-exposing EVs together 
with TF likely contribute to coronary thrombus 
formation. PEVs+ may contribute to coagulation 
also indirectly by activating monocytes interaction 
of PEVs P-selectin with monocyte PSGL-1, lead-
ing to cytokine release and production of TF [9]. 
Thus, by decreasing the concentration of PEV+, 
ticagrelor likely decreases the proinflammatory/
procoagulant surface for interaction between PEVs 
and monocytes/clotting factors, respectively.
Regarding the recently proved inflammatory 
hypothesis of atherosclerosis [29] and the lack of 
consensus regarding the optimal duration of antiplate-
let therapy with P2Y12 antagonists [4], determining 
the effect of P2Y12 antagonists on the release of 
PEVs helps to explain the mechanisms underlying 
decreases in inflammation/thrombosis for patients 
treated with P2Y12 antagonists. To determine the 
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Figure 5. Proposed procoagulant activity of platelet extracellular vesicles (PEVs) in plasma. Fibrin generation test was 
performed in platelet-depleted, but PEVs-containing plasma stimulated with adenosine diphosphate (ADP). A part 
of PEVs expose phosphatidylserine (CD61+/PS+) (A). When the plasma clots, the optical density increases (B). ADP-
-stimulated plasma containing phosphatidylserine (PS)-exposing extracellular vesicles (EVs) did not clot (red). Upon 
the addition of recombinant human tissue factor (TF) to this plasma, clotting was triggered as measured by fibrin 
generation (blue). The extent of clotting was not affected by the presence of the P2Y1 and P2Y12 receptor antagonists 
(data not shown). Covering PS-exposing EVs with an excess of lactadherin, or inhibiting the TF-initiated extrinsic 
coagulation with an anti-factor VIIa antibody, both inhibited plasma clotting (black and green, respectively). Hence, 
both PS-containing EVs and TF are indispensable for propagation of coagulation.
www.cardiologyjournal.org 787
Aleksandra Gasecka et al., Ticagrelor inhibits the release of platelet extracellular vesicles
effects of the P2Y12 antagonists on the release of 
PEVs in a clinical setting, the AFFECT EV (Antiplate-
let therapy effect on platelet extracellular vesicles, 
NCT02931045) study was launched [30]. AFFECT 
EV compares the effects of clopidogrel and ticagrelor 
on the release of PEVs in patients with ACS, with 
the hypothesis that more potent platelet inhibition 
is associated with larger decrease of PEV release.
Limitations of the study
First, the study was limited by the relatively 
small size of the study population, and therefore the 
presented results and conclusions should be consid-
ered as hypothesis-generating. Second, the decrease 
in the release of proinflammatory/procoagulant PEVs 
by ticagrelor was observed under experimental con-
ditions only, and requires confirmation in a clinical 
setting. Third, the study identifies only one potential 
mechanism of the combined anti-thrombotic and 
anti-inflammatory benefits of the P2Y12 receptor 
antagonists — decrease of the release of PEVs. Since 
activated platelets release other proinflammatory/ 
/procoagulant molecules along with PEVs, it is likely 
that other mechanisms contribute to clinical benefits 
of the P2Y12 receptor antagonists as well. 
Conclusions 
Despite extensive research into the role and 
clinical applications of PEVs, the mechanisms regu-
lating the release of PEVs as well as the effects of 
widely used drugs on the release of PEVs remain 
to be defined. The present results demonstrate 
that ADP-activated platelets released two distinct 
subpopulations of PEVs, which differ in their sen-
sitivity to inhibition of P2Y1 and P2Y12 receptors. 
The release of (likely) proinflammatory and proco-
agulant PEVs is decreased by the P2Y12 antagonist 
ticagrelor, identifying a potential mechanism un-
derlying attenuated inflammation and thrombosis 
in patients treated with P2Y12 antagonists. Further 
research is warranted to confirm this mechanism 
in vitro as well as in vivo.
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Figure 6. The potential proinflammatory and procoagulant effects of platelet extracellular vesicles (PEVs). PEVs 
contribute to coagulation both directly by providing procoagulant surface (phosphatidylserine) for the assem-
bly of coagulation factors, and indirectly by binding of P-selectin to P-selectin glycoprotein ligand-1 (PSGL-1) 
on monocytes, leading to an exposure of tissue factor on monocytes. In addition, interaction between P-selectin and 
PSGL-1 contributes to inflammation by stimulating the release of pro-inflammatory cytokines from monocytes.
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